FORM	4

(D.

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Rubin Steven D	Reporting Person +	1	2. Issuer Name and Ticker or Trading Symbol eXegenics Inc [EXEG]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
4400 BISCAYNE BO	^(First) DULEVARD, 157		3. Date of Earliest Transaction (Month/Day/Year) 03/27/2007					Officer (give title below) Oth	er (specify below	w)	
(Street) MIAMI, FL 33137			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu					Acqui	red, Disposed of, or Beneficially Own	ed	
1. Title of Security (Instr. 3)		2. Transaction 2A. Deemed 3. Transaction 4. Securities Acquired Date Execution Date, if Code (A) or Disposed of (D (Month/Day/Year) any (Instr. 8) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s)	6. Ownership Form:	Beneficial				
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownershij (Instr. 4)
Common Stock		03/27/2007		А		4,095,581	А	(1)	4,095,581	D	
Common Stock									15,490,546	Ι	See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

			Table II						ea oi, or Bene vertible secur		ncu																		
Security	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and		Expiration Date (Month/Day/Year) or D)		Expiration Date		Expiration Date (Month/Day/Year)		Expiration Date		Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)															
Warrants (Right to Buy)	\$ 0.6728	03/27/2007		А		345,480		<u>(3)</u>	03/27/2017	Common Stock	345,480	<u>(1)</u>	345,480	D															
Warrants (Right to Buy)	\$ 0.8473	03/27/2007		А		345,480		<u>(3)</u>	03/27/2017	Common Stock	345,480	<u>(1)</u>	345,480	D															
Warrants (Right to Buy)	\$ 1.0466	03/27/2007		А		345,480		<u>(3)</u>	03/27/2017	Common Stock	345,480	<u>(1)</u>	345,480	D															
Warrants (Right to Buy)	\$ 0.4984	03/27/2007		A		4,000,000		<u>(3)</u>	03/27/2017	Common Stock	4,000,000	<u>(4)</u>	4,000,000	Ι	See Footnote (2)														
Warrants (Right to Buy)	\$ 0.0002	03/27/2007		А		81,085		<u>(3)</u>	01/11/2017	Common Stock	81,085	<u>(5)</u>	81,085	Ι	See Footnote (2)														
Warrants (Right to Buy)		03/27/2007		А		6,487		<u>(3)</u>	01/11/2017	Common Stock	648,700	<u>(5)</u>	6,487	Ι	See Footnote (2)														
Warrants (Right to Buy)		03/27/2007		А		22,124		<u>(3)</u>	03/27/2017	Common Stock	22,124	<u>(5)</u>	22,124	Ι	See Footnote (2)														
Warrants (Right to Buy)	\$ 0.8473	03/27/2007		А		22,124		<u>(3)</u>	03/27/2017	Common Stock	22,124	<u>(5)</u>	22,124	Ι	See Footnote (2)														
Warrants (Right to Buy)	\$ 1.0467	03/27/2007		А		22,125		<u>(3)</u>	03/27/2017	Common Stock	22,125	<u>(5)</u>	22,125	Ι	See Footnote (2)														

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Rubin Steven D						

4400 BISCAYNE BOULEVARD	Х		
15TH FLOOR			
MIAMI, FL 33137			

Signatures

/s/ Steven D. Rubin	03/29/2007
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person acquired these securities in connection with the merger of Froptix Corporation into a wholly-owned subsidiary of the issuer in exchange for securities of Froptix held by the reporting person immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was \$3.28.
- (2) These securities are owned directly by The Frost Group, LLC. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- (3) These warrants are immediately exercisable.
- (4) These warrants were acquired by The Frost Group as part of the consideration paid by the issuer for a line of credit extended by The Frost Group to the issuer in connection with the merger.
- (5) The Frost Group acquired these securities in connection with the merger of Acuity Pharmaceuticals, Inc. into a wholly-owned subsidiary of the issuer in exchange for securities of Acuity held by The Frost Group immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was \$3.28 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.